Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?

• Aurélien Mary,
• Aurélien Mary,
• Lucie Hénaut,
• Jean-Luc Schmit,
• Jean-Luc Schmit,
• Jean-Philippe Lanoix,
• Jean-Philippe Lanoix,
• Michel Brazier,
• Michel Brazier

Affiliations

Aurélien Mary

Clinical Critical Care Pharmacy Department, Amiens-Picardie University Hospital, Amiens, France

Aurélien Mary

UR UPJV 7517, MP3CV, CURS, University of Picardie Jules Verne, Amiens, France

Lucie Hénaut

UR UPJV 7517, MP3CV, CURS, University of Picardie Jules Verne, Amiens, France

Jean-Luc Schmit

Infectious Diseases Department, Amiens-Picardie University Hospital, Amiens, France

Jean-Luc Schmit

AGIR UR UPJV 4294, CURS, University of Picardie Jules Verne, Amiens, France

Jean-Philippe Lanoix

Infectious Diseases Department, Amiens-Picardie University Hospital, Amiens, France

Jean-Philippe Lanoix

AGIR UR UPJV 4294, CURS, University of Picardie Jules Verne, Amiens, France

Michel Brazier

UR UPJV 7517, MP3CV, CURS, University of Picardie Jules Verne, Amiens, France

Michel Brazier

Department of Biochemistry, Amiens-Picardie University Hospital, Amiens, France